Posted on Fri 4 Sep 2020, 04:07 PM

Patients involved in early tests of a Russian coronavirus vaccine developed antibodies with “no serious adverse events”, according to research published in The Lancet Friday, but experts said the trials were too small to prove safety and effectiveness.

Russia announced last month that its vaccine, named “Sputnik V” after the Soviet-era satellite that was the first launched into space in 1957, had already received approval.

This raised concerns among Western scientists over a lack of safety data, with some warning that moving too quickly on a vaccine could be dangerous.

Subscribe to RSS - Early Trial.
Get the Latest News updates from Homeland New. Read more
Phone: +234 818 217 4858
Email: info@homelandnewsng.com

Newsletter

Subscribe to our Newsletter to get latest updates!

Connect With Us